DrugBank 5.0: a major update to the DrugBank database for 2018
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
DrugBank (www.drugbank.ca) is a web-enabled database containing comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. First described in 2006, DrugBank has continued to evolve over the past 12 years in response to marked improvements to web standards and changing needs for drug research and development. This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years. In many cases, existing data content has grown by 100% or more over the last update. For instance, the total number of investigational drugs in the database has grown by almost 300%, the number of drug-drug interactions has grown by nearly 600% and the number of SNP-associated drug effects has grown more than 3000%. Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions. A great deal of brand new data have also been added to DrugBank 5.0. This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoprotoemics). New data have also been added on the status of hundreds of new drug clinical trials and existing drug repurposing trials. Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacological research, pharmaceutical science and drug education.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DrugBank primarily contains drug indications extracted from drug labels, while MEDI utilizes public internet sources to drug indications, and is a well utilized resource of drug indications.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, we searched DrugBank84 to identify therapeutic compounds targeting AD-associated proteins. Of the 38 proteins, 15 had reported molecules (Fig. 4D).”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [84]
In the citing paper
“AVPR2 and NPR1 genes play pivotal roles in regulating fluid and electrolyte balance via complementary but distinct pathways. AVPR2 contributes to water retention and urine concentration, whereas NPR1 facilitates vasodilatation, lowers blood pressure and enhances water excretion47.”
From A foundation model for clinician-centered drug repurposing (2024) · cites this paper as [47]
In the citing paper
“In essence, the CC is an alternative representation of the small-molecule knowledge deposited in the public domain and, as such, it is also limited by the availability of experimental data and the coverage of its source databases (e.g., ChEMBL9 or DrugBank10).”
From Bioactivity descriptors for uncharacterized chemical compounds (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · cited 1×
“DrugBank 1.0, released in 2006, provided novel (at the time) physico-chemical data on selected FDA-approved drugs and their drug-targets (2).”
BackgroundInfluentialSelf-citationDrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861 · cited 1×
“DrugBank 2.0, released in 2008, added pharmacological, pharmacogenomic and molecular biological data (3).”
BackgroundInfluentialSelf-citationThe new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)
MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1133 · Cited by 2,161 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
BackgroundDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 1×
“tion, distribution, metabolism, excretion and toxicity) data (5).”
Self-citationDrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831 · cited 1×
“DrugBank 3.0, released in 2010, added drug–drug and drug–food interactions, drug transporter data as well as pharmacokinetic information (4).”
BackgroundInfluentialSelf-citationClassyFire: automated chemical classification with a comprehensive, computable taxonomy
Djoumbou Feunang, Y., Eisner, R., Knox, C., Chepelev, L., Hastings, J., Owen, G., Fahy, E., Steinbeck, C., Subramanian, S., Bolton, E., et al. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0174-y · Cited by 1,525
Self-citationThe Comparative Toxicogenomics Database: update 2017
Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., King, B. L., McMorran, R., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw838 · Cited by 544 · cited 1×
“Additional pharmacoproteomic and pharmacotranscriptomic data were obtained from the CTD (18).”
MethodPredicting drug metabolism: experiment and/or computation?
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4581 · Cited by 502 · cited 1×
“It has also become much more robust and sophisticated (21).”
BackgroundAllen, F., Pon, A., Wilson, M., Greiner, R., & Wishart, D. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku436 · Cited by 464 · cited 7×
“In particular, CFM-ID (19) and CFM-ID 2.”
BackgroundInfluentialSelf-citationSim, S. C., & Ingelman-Sundberg, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-4-278 · Cited by 216 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
Background
Cited by
Items 301–400 of 1,056
Sequence-based drug design as a concept in computational drug design
Chen, L., Fan, Z., Chang, J., Yang, R., Hou, H., Guo, H., Zhang, Y., Yang, T., Zhou, C., Sui, Q., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39856-w · Cited by 124
“0 was applied to score 2204 human proteins from the DrugBank database 55 against four classic PPIs (rabeprazole, lansoprazole, omeprazole and pantoprazole, Fig.”
Algal-based removal strategies for hazardous contaminants from the environment – A review
Tolboom, S. N., Carrillo-Nieves, D., de Jesús Rostro-Alanis, M., de la Cruz Quiroz, R., Barceló, D., Iqbal, H. M. N., & Parra-Saldivar, R. (2019) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.02.129 · Cited by 125
Sun, Y., Wu, P., Zhang, Z., Wang, Z., Zhou, K., Song, M., Ji, Y., Zang, F., Lou, L., Rao, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.010 · Cited by 140
Methanogenic archaea in the human gastrointestinal tract
Högenauer, C., Hammer, H. F., Mahnert, A., & Moissl‐Eichinger, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00673-z · Cited by 146
Uni-Dock: GPU-Accelerated Docking Enables Ultralarge Virtual Screening
Yu, Y., Cai, C., Wang, J., Bo, Z., Zhu, Z., & Zheng, H. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c01145 · Cited by 106
The role of endothelial cell–pericyte interactions in vascularization and diseases
Li, G., Gao, J., Ding, P., & Gao, Y. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.01.016 · Cited by 140
Machine Learning in Pharmacometrics: Opportunities and Challenges
McComb, M., Bies, R., & Ramanathan, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14801 · Cited by 128
In silico approaches and tools for the prediction of drug metabolism and fate: A review
Kazmi, S. R., Ren, J., Yu, M., Jung, C., & Na, D. (2019) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2019.01.008 · Cited by 137
Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput ScreeningPreprint
Li, Y., Zhang, J., Wang, N., Li, H., Shi, Y., Guo, G., Liu, K., Zeng, H., & Zou, Q. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.28.922922 · Cited by 135
Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development
Huang, F., Han, X., Xiao, X., & Zhou, J. (2022) · Molecules · doi:10.3390/molecules27227728 · Cited by 143
“Aryl halide warheads are reported to be relatively abundant in approved and investigational drugs, but their alkyl compounds are rare except for DNA alkylating agents [51].”
BackgroundExtending the small-molecule similarity principle to all levels of biology with the Chemical Checker
Duran-Frigola, M., Pauls, E., Guitart-Pla, O., Bertoni, M., Alcalde, V., Amat, D., Juan-Blanco, T., & Aloy, P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0502-7 · Cited by 126
Virtual Screening Techniques in Drug Discovery: Review and Recent Applications
Rocha, S. F. L. D. S., Olanda, C. G., Fokoue, H. H., & Sant’Anna, C. M. R. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190816101948 · Cited by 138
A map of the amine–carboxylic acid coupling system
Mahjour, B. A., Shen, Y., Liu, W., & Cernak, T. (2020) · Nature · doi:10.1038/s41586-020-2142-y · Cited by 134
Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.023 · Cited by 118
Cheng, L., Qi, C., Zhuang, H., Fu, T., & Zhang, X. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa511 · Cited by 139
Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace
Singh, N., Chaput, L., & Villoutreix, B. O. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa034 · Cited by 137
“The data sources include ChEMBL [168], BindingDB [207], DrugBank [171], STITCH [208] .”
BackgroundMethodInfluentialToxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics
Abdelsalam, N. A., Ramadan, A. T., ElRakaiby, M. T., & Aziz, R. K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00390 · Cited by 122
“CYP1A2 affects potent medications as theophylline, psychological disorders medications, warfarin, and other anticancer drugs (Wishart et al., 2018).”
BackgroundAttention-based Knowledge Graph Representation Learning for Predicting Drug-drug Interactions
Su, X., Hu, L., You, Z., Hu, P., & Zhao, B.-W. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac140 · Cited by 136
Liu, R., Wei, L., & Zhang, P. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-020-00276-w · Cited by 117
Dong, Y., Zhao, Q., & Wang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-98925-6 · Cited by 136
Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus
Zu, G., Sun, K., Li, L., Zu, X., Han, T., & Huang, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-02248-5 · Cited by 140
Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms
Jiang, J., Ma, X., Ouyang, D., & Williams, R. O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112257 · Cited by 144
“DrugBank >500,000 University of Alberta [44]”
Comprehensive evaluation of deep and graph learning on drug–drug interactions prediction
Lin, X., Dai, L., Zhou, Y., Yu, Z., Zhang, W., Shi, J., Cao, D., Li, Z., Chen, H., Song, B., et al. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad235 · Cited by 132
Genome-wide identification and analysis of prognostic features in human cancers
Smith, J. C., & Sheltzer, J. M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110569 · Cited by 134
RCSB Protein Data bank: Tools for visualizing and understanding biological macromolecules in 3D
Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chao, H., Chen, L., Craig, P., Crichlow, G. V., Dalenberg, K., Duarte, J. M., et al. (2022) · Protein Science · doi:10.1002/pro.4482 · Cited by 141
Gottschlich, A., Thomas, M., Grünmeier, R., Lesch, S., Rohrbacher, L., Igl, V., Briukhovetska, D., Benmebarek, M.-R., Vick, B., Dede, S., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01684-0 · Cited by 139
“Thus, we used an accessible database of all monitored FDA-approved drugs that contains information on the interactions, pharmacology and chemical structures of drugs and drug targets 38 .”
MethodMetabolomics and complementary techniques to investigate the plant phytochemical cosmos
Tsugawa, H., Rai, A., Saito, K., & Nakabayashi, R. (2021) · Natural Product Reports · doi:10.1039/d1np00014d · Cited by 126
Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling
Beckwitt, C. H., Shiraha, K., & Wells, A. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197422 · Cited by 129
Alshehri, A. S., Gani, R., & You, F. (2020) · Computers & Chemical Engineering · doi:10.1016/j.compchemeng.2020.107005 · Cited by 131
Lokhande, K. B., Doiphode, S., Vyas, R., & Swamy, K. V. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1805019 · Cited by 124
“The 2-dimensional structures of Antiviral Drugs and FDA approved drugs were obtained from Selleckchem Inc. (Houston, TX, https://www.selleckchem.com/h) and Drug Bank database (Wishart et al., 2018) respectively.”
MethodNP-MRD: the Natural Products Magnetic Resonance Database
Wishart, D. S., Sayeeda, Z., Budinski, Z., Guo, A., Lee, B. L., Berjanskii, M. V., Rout, M. K., Peters, H., Dizon, R., Mah, R., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1052 · Cited by 129
“As with other databases developed in the Wishart laboratory (2,20), all chemical structures in the NP-MRD are hosted on a specially developed structure server called ‘Moldb’ and all NPMRD spectral data are hosted on a server called ‘Specdb’.”
MethodSelf-citationMarkerDB: an online database of molecular biomarkers
Wishart, D. S., Bartok, B., Oler, E., Liang, K. Y. H., Budinski, Z., Berjanskii, M. V., Guo, A., Cao, X. D., & Wilson, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1067 · Cited by 128
Self-citationMiMeDB: the Human Microbial Metabolome Database
Wishart, D. S., Oler, E., Peters, H., Guo, A., Girod, S., Han, S., Saha, S., Lui, V. W., LeVatte, M., Gautam, V., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac868 · Cited by 131
“MiMeDB was assembled with the same quality assurance, quality control and quality management procedures implemented for all the databases developed by our group, including HMDB (23), DrugBank (31), YMDB (27) and ECMDB (24).”
MethodSelf-citationMolecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19
Talluri, S. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200814132149 · Cited by 126
A review on compound-protein interaction prediction methods: Data, format, representation and model
Lim, S., Lu, Y., Cho, C. Y., Sung, I., Kim, J., Kim, Y., Park, S., & Kim, S. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.03.004 · Cited by 119
Predicting Solubility Limits of Organic Solutes for a Wide Range of Solvents and Temperatures
Vermeire, F. H., Chung, Y., & Green, W. H. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c01768 · Cited by 119
Characterization of the Chemical Space of Known and Readily Obtainable Natural Products
Chen, Y., de Lomana, M. G., Friedrich, N., & Kirchmair, J. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00302 · Cited by 127
Highlights in Resistance Mechanism Pathways for Combination Therapy
Delou, J. M. D. A., Souza, A. S. O., Souza, L. C. D. M. E., & Borges, H. L. (2019) · Cells · doi:10.3390/cells8091013 · Cited by 128
“We highlighted the most clinically relevant information from selected articles (Pubmed), clinical trials (ClinicalTrials.gov), and the curated databases Drugbank [13] and SuperCYP/Transformer [14] relating to drug resistance mechanisms.”
Agoni, C., Olotu, F. A., Ramharack, P., & Soliman, M. E. S. (2020) · Journal of Molecular Modeling · doi:10.1007/s00894-020-04385-6 · Cited by 129
Dreßler, L., Bortolomeazzi, M., Keddar, M. R., Mišetić, H., Sartini, G., Acha‐Sagredo, A., Montorsi, L., Wijewardhane, N., Repana, D., Nulsen, J., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02607-z · Cited by 131
“Original data were obtained from the following online sources: 1000 Genomes Project Phase 3 [103] v.5a: https://www.internationalgenome.org/category/phase-3/ BioGRID [93] v.3.5.185: https://thebiogrid.org/ Bioplex [97] v.3.0: https://bioplex.hms.harvard.edu/interactions.php CORUM [98] v.3.0: http://mips.helmholtz-muen…”
MethodInfluentialTrigeminal-based Temperature Illusions
Brooks, J., Nagels, S., & Lopes, P. (2020) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3313831.3376806 · Cited by 127
Natural product fragment combination to performance-diverse pseudo-natural products
Grigalunas, M., Burhop, A., Zinken, S., Pahl, A., Gally, J., Wild, N., Mantel, Y., Sievers, S., Foley, D. J., Scheel, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22174-4 · Cited by 116
Lungu, I.-A., Moldovan, O.-L., Biriș, V., & Rusu, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081749 · Cited by 128
Zhao, B.-W., Su, X., Hu, P., Huang, Y., You, Z., & Hu, L. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad451 · Cited by 126
“0 due to the update of this database (Wishart et al. 2018).”
BackgroundMethodXu, J., Mao, C., Hou, Y., Luo, Y., Binder, J. L., Zhou, Y., Bekris, L. M., Shin, J., Hu, M., Wang, F., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111717 · Cited by 115
“129 To predict drugs using the extracted disease module from NETTAG, we adopted the closest-based network proximity measure 70 shown below.”
MethodTrezza, A., Iovinelli, D., Santucci, A., Prischi, F., & Spiga, O. (2020) · Scientific Reports · doi:10.1038/s41598-020-70863-9 · Cited by 118
Deep Learning in Drug Target Interaction Prediction: Current and Future Perspectives
Abbasi, K., Razzaghi, P., Poso, A., Ghanbari-Ara, S., & Masoudi‐Nejad, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200907141016 · Cited by 140
Dapaah, M. F., Niu, Q., Yu, Y., You, T., Liu, B., & Cheng, L. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.134182 · Cited by 118
Drug-drug interactions prediction based on deep learning and knowledge graph: A review
Luo, H., Yin, W., Wang, J., Zhang, G., Liang, W., Luo, J., & Yan, C. (2024) · iScience · doi:10.1016/j.isci.2024.109148 · Cited by 131
Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
Tsafou, K., Tiwari, P. B., Forman-Kay, J. D., Metallo, S. J., & Toretsky, J. A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.008 · Cited by 112
Cavasotto, C. N., & Filippo, J. I. D. (2020) · Molecular Informatics · doi:10.1002/minf.202000115 · Cited by 120
FlowGNN: A Dataflow Architecture for Real-Time Workload-Agnostic Graph Neural Network Inference
Sarkar, R., Abi-Karam, S., He, Y., Sathidevi, L., & Hao, C. (2023) · IEEE International Symposium on High-Performance Computer Architecture (HPCA) · doi:10.1109/hpca56546.2023.10071015 · Cited by 145
Domingo‐Fernándéz, D., Gadiya, Y., Preto, A. J., Krettler, C. A., Mubeen, S., Allen, A., Healey, D., & Colluru, V. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00581 · Cited by 124
Advancing pharmaceutical research: A comprehensive review of cutting-edge tools and technologies
Chen, J., Lin, A., & Luo, P. (2024) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2024.11.001 · Cited by 112
Soluble ligands as drug targets
Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 120
Chen, Y., Rosenkranz, C., Hirte, S., & Kirchmair, J. (2022) · Natural Product Reports · doi:10.1039/d2np00001f · Cited by 122
Zhao, B.-W., Wang, L., Hu, P., Wong, L., Su, X., Wang, B., You, Z., & Hu, L. (2023) · IEEE Transactions on Emerging Topics in Computing · doi:10.1109/tetc.2023.3239949 · Cited by 116
“…drugs obtained by the RD-kit toolkit [22] to deal with the Simplified Molecular Input Line Entry System (SMILES) [23] derived from DrugBank database [24]; C di is the semantic similarity matrix of diseases constructed with the data of Medical Subject heading (MeSH) descriptor [25] that can be…”
MethodDeep Generative Models in De Novo Drug Molecule Generation
Pang, C., Qiao, J., Zeng, X., Zou, Q., & Wei, L. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01496 · Cited by 144
Cruchaga, C., Western, D., Timsina, J., Wang, L., Wang, C., Yang, C., Ali, M., Beric, A., Gorijala, P., Kohlfeld, P., et al. (2023) · doi:10.21203/rs.3.rs-2814616/v1 · Cited by 112
Western, D., Timsina, J., Wang, L., Wang, C., Yang, C., Phillips, B., Wang, Y., Liu, M., Ali, M., Beric, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01972-8 · Cited by 111
“Fcγ receptor IIIb (FCGR3B) is targeted by cetuximab (DrugBank accession number DB00002), a chemotherapy agent.”
Hit Dexter 2.0: Machine-Learning Models for the Prediction of Frequent Hitters
Stork, C., Chen, Y., Šícho, M., & Kirchmair, J. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00677 · Cited by 110
A systems approach to infectious disease
Eckhardt, M., Hultquist, J. F., Kaake, R. M., Hüttenhain, R., & Krogan, N. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0212-5 · Cited by 112
Çelebi, R., Uyar, H. T., Yasar, E., Gümüş, Ö., Dikenelli, O., & Dumontier, M. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3284-5 · Cited by 127
Ligands of Adrenergic Receptors: A Structural Point of View
Wu, Y., Zeng, L., & Zhao, S. (2021) · Biomolecules · doi:10.3390/biom11070936 · Cited by 121
“org, accessed on 25, April 2021), and DrugBank [17] (go.”
BackgroundSu, X., You, Z., Huang, D.-S., Wang, L., Wong, L., Ji, B., & Zhao, B.-W. (2022) · IEEE Transactions on Knowledge and Data Engineering · doi:10.1109/tkde.2022.3154792 · Cited by 136
“There are 10,533 approved drugs, 1,195,972 approved DDIs and 39 types of DDI relationships in it; DrugBank [55]. we parse the verified DDIs of provided profile from DrugBank and compile an edge list of drug identifier combinations, which obtains 3,797 approved small molecule drugs and 1,236,361…”
BackgroundComprehensive Survey of Consensus Docking for High-Throughput Virtual Screening
Blanes‐Mira, C., Fernández-Aguado, P., de Andrés-López, J., Fernández-Carvajal, A. M., Ferrer-Montiel, A. V., & Fernandez-Ballester, G. J. (2022) · Molecules · doi:10.3390/molecules28010175 · Cited by 124
“Databases such as DrugBank [84] and the Human Metabolome Database [85] are commonly used to repurpose approved drugs to novel targets.”
BackgroundHanks, G. E., Hanlon, A., Pinover, W. H., Horwitz, E. M., & Schultheiss, T. E. (1999) · PubMed · Cited by 110
Baylon, J. L., Cilfone, N. A., Gulcher, J. R., & Chittenden, T. W. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00801 · Cited by 122
SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19
Fiscon, G., Conte, F., Farina, L., & Paci, P. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008686 · Cited by 115
“Note that, for some drugs of interest for which no targets were found in DrugBank, we integrated drug-target interactions available from Therapeutic Target Database (TTD) 79 and Pharmacogenomics Knowledgebase (PharmGKB) 80 database.”
BackgroundMethodInfluentialBa, X., Huang, Y., Shen, P., Huang, Y., Wang, H., Han, L., Lin, W., Yan, H., Xu, L. J., Qin, K., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.696802 · Cited by 307
“For disease target identification, RA-related target proteins were screened from the DrugBank (Wishart et al., 2018), OMIM (Amberger et al., 2015), pharmGK (Barbarino et al., 2018), Therapeutic Target database (Wang et al., 2020), DisGeNET (Pinero et al., 2017) and GeneCards (Stelzer et al., 2016) databases by using t…”
Péris-Vicente, J., Peris-García, E., Albiol-Chiva, J., Durgbanshi, A., Ochoa-Aranda, E., Carda‐Broch, S., Bose, D., & Esteve‐Romero, J. S. (2022) · Microchemical Journal · doi:10.1016/j.microc.2022.107309 · Cited by 109
Fluorinated Cycloalkyl Building Blocks for Drug Discovery
Grygorenko, O. O., Melnykov, K. P., Holovach, S. M., & Demchuk, O. P. (2022) · ChemMedChem · doi:10.1002/cmdc.202200365 · Cited by 113
Biomarkers for major depressive and bipolar disorders using metabolomics: A systematic review
MacDonald, K., Krishnan, A., Cervenka, E., Hu, G., Guadagno, E., & Trakadis, Y. J. (2018) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32680 · Cited by 114
Deshpande, R. R., Tiwari, A. P., Nyayanit, N., & Modak, M. A. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173430 · Cited by 117
Chen, S., Li, B., Chen, L., & Jiang, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04233-0 · Cited by 118
“Drug targets of RES DrugBank is a comprehensive, freely available web-based bioinformatics and cheminformatics database containing detailed drug data and comprehensive information on drug targets, drug actions, and drug interactions [22].”
BackgroundOchiai, T., Inukai, T., Akiyama, M., Furui, K., Ohue, M., Matsumori, N., Inuki, S., Uesugi, M., Sunazuka, T., Kikuchi, K., et al. (2023) · Communications Chemistry · doi:10.1038/s42004-023-01054-6 · Cited by 129
Network medicine framework for identifying drug-repurposing opportunities for COVID-19
Morselli Gysi, D., do Valle, Í., Zitnik, M., Ameli, A., Gan, X., Varol, O., Ghiassian, S. D., Patten, J. J., Davey, R. A., Loscalzo, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025581118 · Cited by 107
“…tests the hypothesis that removing the protein targets involved in drug delivery and drug metabolism, shared by multiple drugs, can improve the specificity of the proximity measure; and P3 (Dataset S4) tests if drug-induced differentially expressed genes can offer additional predictive power (27).”
BackgroundMethodWhole-genome sequencing analysis of the cardiometabolic proteome
Gilly, A., Park, Y.-C., Png, G., Barysenka, A., Fischer, I., Bjørnland, T., Southam, L., Suveges, D., Neumeyer, S., Rayner, N. W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20079-2 · Cited by 107
Integrated Computational Approaches and Tools for Allosteric Drug Discovery
Amamuddy, O. S., Veldman, W., Manyumwa, C. V., Khairallah, A., Agajanian, S., Odeyemi, O., Verkhivker, G. M., & Bishop, Ö. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030847 · Cited by 119
“Despite continually growing investment in allosteric research, only 19 of these modulators are approved drugs compared to the current total of more than 3700 approved drugs [136,137], almost all of which bind to an orthosteric site [138].”
BackgroundApplication of network link prediction in drug discovery
Abbas, K., Abbasi, A., Dong, S., Ling, N., Yu, L., Chen, B., Cai, S., & Hasan, Q. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04082-y · Cited by 122
“A drug–drug relationship is formed when the pharmacological effect of one drug is affected by another drug [85].”
BackgroundMethodAlkaloidal Phytoconstituents for Diabetes Management: Exploring the Unrevealed Potential
Behl, T., Gupta, A. K., Albratty, M., Najmi, A., Meraya, A. M., Alhazmi, H. A., Anwer, M. K., Bhatia, S., & BUNGAU, S. G. (2022) · Molecules · doi:10.3390/molecules27185851 · Cited by 135
“As reported by the DrugBank, more than 95% of FDA-approved antidiabetic medicines are associated with T2D by facilitating insulin secretion and thereby reducing blood glucose levels [14].”
BackgroundPei, Q., Zhang, W., Zhu, J., Wu, K., Gao, K., Wu, L., Xia, Y., & Yan, R. (2023) · Conference on Empirical Methods in Natural Language Processing (EMNLP) · doi:10.18653/v1/2023.emnlp-main.70 · Cited by 190
Drug target prediction through deep learning functional representation of gene signatures
Chen, H., King, F. J., Zhou, B., Wang, Y., Canedy, C. J., Hayashi, J., Zhong, Y., Chang, M. W., Pache, L., Wong, J. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46089-y · Cited by 119
“We extracted subnetworks formed by compounds and their top candidate targets for each separate anatomical therapeutic chemical (ATC) classi fi cation according to DrugBank 52 .”
Liganding Functional Tyrosine Sites on Proteins Using Sulfur–Triazole Exchange Chemistry
Brulet, J. W., Borne, A. L., Yuan, K., Libby, A. H., & Hsu, K.-L. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c00648 · Cited by 101
Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI)
Minerali, E., Foil, D. H., Zorn, K. M., Lane, T. R., & Ekins, S. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00326 · Cited by 112
Yang, J., Tian, S., Zhao, J., & Zhang, W. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105034 · Cited by 112
Khelfaoui, H., Harkati, D., & Saleh, B. A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1803967 · Cited by 110
StreptomeDB 3.0: an updated compendium of streptomycetes natural products
Moumbock, A. F. A., Gao, M., Qaseem, A., Li, J., Kirchner, P. A., Ndingkokhar, B., Bekono, B. D., Simoben, C. V., Babiaka, S. B., Malange, Y. I., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa868 · Cited by 115
Yang, Q., Li, B., Chen, S., Tang, J., Li, Y., Li, Y., Zhang, S., Shi, C., Zhang, Y., Mou, M., et al. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.104023 · Cited by 108
“…literature reviews and by using information from available metabolite databases (HMDB [56], T3DB [62], ECMDB [63], YMDB [64], PMDB [65], Drugbank [66], CFAM [67], TCMID [68], KEGG [69], etc.), which provided abundant information on the exogenous factors of human life (food, plant, drug,…”
BackgroundMetal‐Free Electrochemical Synthesis of Sulfonamides Directly from (Hetero)arenes, SO 2 , and Amines
Blum, S. P., Karakaya, T., Schollmeyer, D., Klapars, A., & Waldvogel, S. R. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202016164 · Cited by 106
Revealing the role of the human blood plasma proteome in obesity using genetic drivers
Zaghlool, S. B., Sharma, S., Molnar, M., Matías-García, P. R., Elhadad, M. A., Waldenberger, M., Peters, A., Rathmann, W., Graumann, J., Gieger, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21542-4 · Cited by 102
Photoaffinity labelling strategies for mapping the small molecule–protein interactome
Burton, N. R., Kim, P., & Backus, K. M. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob01353j · Cited by 115
TOXRIC: a comprehensive database of toxicological data and benchmarks
Wu, L., Yan, B., Han, J., Li, R., Xiao, J., He, S., & Bo, X. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1074 · Cited by 120
“Target proteins of compounds are collected from DrugBank (40) and BindingDB (41) database in text format.”
Absorption matters: A closer look at popular oral bioavailability rules for drug approvals
Soares, A. C. G., Sousa, G. H. M., Calil, R. L., & Trossini, G. H. G. (2023) · Molecular Informatics · doi:10.1002/minf.202300115 · Cited by 124
Chinn, A. J., Sedillo, K., & Doyle, A. G. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c09484 · Cited by 105
Tran, T. T. V., Tayara, H., & Chong, K. T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041260 · Cited by 124
“It contains information on more than 500,000 drugs and their associated targets, pathways, and metabolic pathways [109].”
BackgroundShtar, G., Rokach, L., & Shapira, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219796 · Cited by 105
“Our evaluation is based on two evaluation schemes: a retrospective analysis using approved drugs from three versions of the DrugBank database [24] and a holdout analysis using a current version of the database.”
MethodPotential Antiviral Options against SARS-CoV-2 Infection
Ianevski, A., Yao, R., Fenstad, M. H., Biza, S., Žusinaite, E., Reisberg, T., Lysvand, H., Løseth, K., Landsem, V. M., Malmring, J. F., et al. (2020) · Viruses · doi:10.3390/v12060642 · Cited by 106
Elucidating Solution Structures of Cyclic Peptides Using Molecular Dynamics Simulations
Damjanovic, J., Miao, J., Huang, H., & Lin, Y.-S. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01087 · Cited by 103
In Silico Methods for Identification of Potential Active Sites of Therapeutic Targets
Liao, J., Wang, Q., Wu, F., & Huang, Z. (2022) · Molecules · doi:10.3390/molecules27207103 · Cited by 115
Metadata
- Authors
- Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., & Wilson, M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Wishart, David S
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-08
- Volume
- 46
- Issue
- D1
- Pages
- D1074-D1082
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5753335
- OpenAlex
- W2767891136
- Cited by
- 8,404
- References
- 22
- Citations by year
- 2026: 617 · 2025: 929 · 2024: 1327 · 2023: 1363 · 2022: 1322 · 2021: 1175 · 2020: 957 · 2019: 502 · 2018: 201 · 2017: 5
- FWCI
- 343.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Genome Canada
- Genome Alberta
- Health Canada
- Canadian Institutes of Health Research
- National Human Genome Research Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- DrugBank, drug databases, drug-drug interactions, food-drug interactions, therapeutic target, drug mechanisms, drug indications, pharmacometabolomics, pharmacoproteomics, drug repurposing, clinical trials, investigational drugs
- MeSH terms
- Drug Interactions, User-Computer Interface, Food-Drug Interactions, Polymorphism, Single Nucleotide, Metabolome, Transcriptome, Databases, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

